Mater Private Network is expanding its radiotherapy service in Limerick, giving public and private cancer patients across the Mid-West access to a broader range of specialist expertise and…
The European Commission has approved AKEEGA® (niraparib and abiraterone acetate) for patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, following Phase 3 data showing a significant delay in disease progression and an early survival benefit.
Limerick Cancer Trials at University Hospital Limerick has been awarded a global Movember grant to develop an evidence-based care pathway for older men with prostate cancer in rural areas, addressing unmet needs and improving equity in cancer care.
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis AUTHOR: E. J. Bass, A.…
